Avecho Biotechnology (ASX:AVE) has disclosed that CEO Dr Paul Gavin presented at BIO-Europe 2026 in Cologne, Germany from 9 to 11 November 2026, during which the company held 40 partnering meetings with potential licensees for its TPM-enhanced cannabidiol soft-gel capsule.
Key Points
- CEO Dr Paul Gavin presented at BIO-Europe 2026 in Cologne, Germany from 9 to 11 November 2026.
- Avecho held 40 partnering meetings with potential licensees over the three days of the conference.
- Meetings included continued discussions with existing parties as well as new parties.
- The company's Phase III trial of its TPM-enhanced CBD soft-gel capsule for insomnia is now recruiting its final cohort following an interim analysis announced in June 2026.
BIO-Europe 2026 Presentation and Conference Details
Avecho Biotechnology disclosed that CEO Dr Paul Gavin presented at BIO-Europe 2026, described in the filing as Europe's flagship biopharmaceutical partnering event, bringing together senior business development, licensing and investment executives from pharmaceutical and biotechnology companies around the world. The conference was held in Cologne, Germany from 9 to 11 November 2026. The company's presentation provided an update on its pivotal Phase III trial of its TPM-enhanced cannabidiol soft-gel capsule for insomnia and the company's strategy to license the product in territories outside Australia.
Partnering Meetings with Potential Licensees
During the conference, Avecho held 40 partnering meetings with potential licensees, according to the filing. These included continued discussions with parties already engaged with the company, as well as meetings with new parties. The filing states the meetings follow the positive interim analysis of Avecho's pivotal Phase III trial announced in June 2026, in which the independent Data Monitoring Board unanimously recommended that the trial continue to its originally planned size of 519 participants without any increase. The company stated it will continue to progress these discussions and will keep the market informed in accordance with its continuous disclosure obligations. The filing noted there is no certainty that any discussion will result in a transaction.
Phase III Trial Recruitment Status
Avecho's pivotal Phase III trial is a multi-centre, randomised, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of CBD TPM soft-gel capsules in adults for the reduction of insomnia severity. According to the filing, the trial is now recruiting its final cohort following the interim analysis announced in June 2026. Trial participants are randomly assigned to receive nightly doses of either 75mg or 150mg of CBD or a placebo for eight weeks. The filing states the trial has been designed to meet the requirements of the Australian Therapeutic Goods Administration, the US Food and Drug Agency, and the European Medicines Agency.




Please wait processing your request...